References
- Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
- Nyman H, Adde M, Karjalainen-Lindsberg ML, et al Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930–4935.
- Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Swerdlow SH, Campo E, Harris NL, et al WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
- Morgan J. A protocol for preparing cell suspensions with formalin fixation and paraffin embedding which minimizes the formation of cell aggregates. J Cell Pathol 2001;5:171–180.
- Drakos E, Rassidakis GZ, Lai R, et al Caspase-3 activation in systemic anaplastic large-cell lymphoma. Mod Pathol 2004;17:109–116.
- Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002;9:459–470.
- Park MJ, Kwon HY, Lee EO, et al DMNQ-S17 inhibits constitutive NF-kappaB activation leading to induction of apoptosis through the activation of caspase-3 in human myeloid leukemia U937 cells. Life Sci 2008;83:460–467.
- Shringarpure R, Catley L, Bhole D, et al Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006;134:145–156.
- Muris JJ, Cillessen SA, Vos W, et al Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005;105:2916–2923.
- Nomura Y, Yoshida S, Karube K, et al Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. Cancer Sci 2008;99:1564–1569.
- Daniels J, Abulayha AM, Thomson BJ, Haynes AP. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 2006;11:1013–1023.
- Eeva J, Nuutinen U, Ropponen A, et al The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells. Apoptosis 2009;14:687–698.
- Zhang L, Qian Z, Cai Z, et al Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84:553–559.
- Carreras J, Lopez-Guillermo A, Fox BC, et al High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957–2964.
- Alvaro T, Lejeune M, Salvador MT, et al Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulation T cells. Clin Cancer Res 2005;11:1467–1473.
- Hasselblom S, Sigurdattir M, Hansson U, Nilsson-Ehle H, Ridell B, Anderson PO. The number of tumour-infiltrating TIA-1 + cytotoxic cells but not FOXP3 + regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007;137:364–373.
- Muris JJ, Ylstra B, Cillessen SA, et al Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol 2007;136:38–47.
- Curiel TJ, Coukos G, Zou L, et al Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced Survival. Nat Med 2004;10:942–949.
- Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3 + regulatory T cells increase during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423–5434.
- Kramer MH, Hermans J, Wijburg E, et al Clinical relevance of Bcl2, Bcl6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152–3162.
- Mounier N, Briere J, Gisselbrecht C, et al Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood 2003;101:4279–4284.